ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 17 No. 4 (2024), LYMPHOID TUMORS
Vol. 17 No. 4 (2024)
LYMPHOID TUMORS

The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease

Published 01.10.2024
Sergei Vyacheslavovich Semochkin
NI Pirogov Russian National Research Medical University, 1 Ostrovityanova ul., Moscow, Russian Federation, 117997; PA Gertsen Moscow Oncology Research Institute, branch of the NMRC of Radiology, 3 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284
https://orcid.org/0000-0002-8129-8114
E.I. Zhelnova
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 8 korp. 2 Trubetskaya ul., Moscow, Russian Federation, 119048
https://orcid.org/0000-0002-0343-9348
V.I. Kazey
Exacte Labs Bioanalytical Laboratory, 20 korp. 2 Nauchnyi pr-d, Moscow, Russian Federation, 117246
https://orcid.org/0000-0003-2032-6289
A.V. Cherkasova
SM Clinic, 22 Simferopolskii b-r, Moscow, Russian Federation, 117452
https://orcid.org/0000-0002-5983-4953
A.G. Nikiforova
Exacte Labs Bioanalytical Laboratory, 20 korp. 2 Nauchnyi pr-d, Moscow, Russian Federation, 117246
https://orcid.org/0000-0002-5719-0787
N.F. Frolova
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; AI Evdokimov Moscow State University of Medicine and Dentistry, 20 Delegatskaya ul., Moscow, Russian Federation, 127243
https://orcid.org/0000-0002-6086-5220
E.A. Baryakh
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 8 korp. 2 Trubetskaya ul., Moscow, Russian Federation, 119048; Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya ul., Moscow, Russian Federation, 125993
https://orcid.org/0000-0001-6880-9269
K.V. Yatskov
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0003-0125-9068
E.A. Karimova
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0001-7603-1741
O.N. Kotenko
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182
https://orcid.org/0000-0001-8264-7374
E.N. Misyurina
Moscow City Clinical Hospital No. 52, 3 Pekhotnaya ul., Moscow, Russian Federation, 123182; IM Sechenov First Moscow State Medical University, 8 korp. 2 Trubetskaya ul., Moscow, Russian Federation, 119048
https://orcid.org/0000-0003-2419-4850
2024-4
PDF_2024-17-4_360-369 (Russian)

Keywords

multiple myeloma
lenalidomide
end-stage renal disease
hemodialysis
cast nephropathy

How to Cite

Semochkin S.V., Zhelnova E.I., Kazey V.I., Cherkasova A.V., Nikiforova A.G., Frolova N.F., Baryakh E.A., Yatskov K.V., Karimova E.A., Kotenko O.N., Misyurina E.N. The Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination as Induction Therapy in Patients with Multiple Myeloma Complicated by the End-Stage Renal Disease. Clinical Oncohematology. 2024;(4):360–369. doi:10.21320/2500-2139-2024-17-4-360-369.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

AIM. To analyze our own experience in the use of the VRd regimen in the induction therapy for patients with newly diagnosed multiple myeloma (MM) complicated by the end-stage renal disease (ESRD).

MATERIALS & METHODS. This prospective cohort trial enrolled 15 newly diagnosed MM patients with ESRD (eGFR < 15 mL/min/1.73 m2) in the period from February to October 2019. Six original RVd induction cycles were planned: lenalidomide 25 mg per os on Days 1, 4, 8, 11, and 15 (administered after hemodialysis), bortezomib 1.3 mg/m2 subcutaneously on Days 1, 4, 8, and 11, as well as dexamethasone 20 mg per os or IV on Days 1, 2, 4, 5, 8, 9, 11, and 12. Blood sampling for pharmacokinetic analysis was performed in 5 (33 %) patients prior to therapy (end-point 0) as well as 4, 24, and 96 hours after the first lenalidomide dose during the 1st RVd cycle.

RESULTS. The median age of patients was 67 years (range 55–74 years); there were 9 women and 6 men. All of them were hemodialysis-dependent. The median GFR was 6.3 (5.7; 12.5) mL/min/1.73 m2. In all patients, the serum β2-microglobuline concentration was > 5.5 mg/L (ISS III = 100 %). In 4 (26.7 %) out of 15 patients, renal response was achieved (group I), whereas 11 (73.3 %) patients showed no renal recovery and remained hemodialysis-dependent (group II). Overall (hematologic) response was 80 % (CR 26.7 %, VGPR 20 %, PR 33.3 %). With the median follow-up of 4.64 years, the 5-year overall survival (OS) in all 15 patients was 33.3 ± 12.2 %. In group I (n = 4), life expectancy of patients was 4.45+, 1.81, 4.93+, and 4,68+ years. Out of them, 3 patients are being further followed-up, one died. In group II (n = 11; 9 events), the median OS was 1.75 years. The median maximum serum lenalidomide concentration as reported 4 hours after the first dose of the drug administration was 470 (364; 496) ng/mL. After 24 hours, the lenalidomide concentration decreased 5.7-fold to 82 (54; 269) ng/mL.

CONCLUSION. The proposed original VRd regimen ensures high rates of overall response (80 %) and deep remissions (³ VGPR 46.7 %). The originality of the VRd regimen consisted in intermittent administration of 25 mg lenalidomide on Days 1, 4, 8, 11, and 15 after hemodialysis reaching a cumulative dose of 125 mg per 21-day cycle. The maximum lenalidomide concentration (Cmax) did not exceed that in patients with normal renal function and gradually decreased by the next hemodialysis session and the next drug administration. The incidence and severity of adverse events did not exceed those resulting from similar regimens for treatment of hemodialysis-dependent MM patients with ESRD.

PDF_2024-17-4_360-369 (Russian)

References

  1. Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13(1):46. doi: 10.1038/s41408-023-00806-w.
  2. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol. 2006;17(9):2533–45. doi: 10.1681/ASN.2006020139.
  3. Dimopoulos MA, Merlini G, Bridoux F, et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023;24(7):e293–e311. doi: 10.1016/S1470-2045(23)00223-1.
  4. Walk JC, Ayati BP, Holstein SA. Modeling the Effects of Multiple Myeloma on Kidney Function. Sci Rep. 2019;9(1):1726. doi: 10.1038/s41598-018-38129-7.
  5. Shafqat A, Elmaleh H, Mushtaq A, et al. Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management. J Clin Med. 2024;13(6):1744. doi: 10.3390/jcm13061744.
  6. Mohan M, Buros A, Mathur P, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–45. doi: 10.1002/ajh.24756.
  7. Tentolouris A, Ntanasis-Stathopoulos I, Eleftheriadou I, et al. Diabetes mellitus and multiple myeloma; common features of two distinct entities. Diabetes Metab Res Rev. 2022;38(5):e3535. doi: 10.1002/dmrr.3535.
  8. Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(Suppl 1):S3–S25. doi: 10.1002/ajh.26512.
  9. Zhu W, Chen W. Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies. Medicine (Baltimore). 2016;95(46):e5202. doi: 10.1097/MD.0000000000005202.
  10. Tan CRC, Abdul-Majeed S, Cael B, Barta SK. Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. Clin Pharmacokinet. 2019;58(2):157–68. doi: 10.1007/s40262-018-0679-9.
  11. Семочкин С.В. Механизмы действия противоопухолевых иммуномодуляторов — от тератогенности к терапии множественной миеломы. Гематология и трансфузиология. 2022;67(2):240–60. doi: 10.35754/0234-5730-2022-67-2-240-260. [Semochkin S.V. Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma. Russian Journal of Hematology and Transfusiology. 2022;67(2):240–60. doi: 10.35754/0234-5730-2022-67-2-240-260. (In Russ)]
  12. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47(12):1466–75. doi: 10.1177/0091270007309563.
  13. Chen CI, Cao Y, Trudel S, et al. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines. Leuk Lymphoma. 2020;61(8):1860–8. doi: 10.1080/10428194.2020.1747064.
  14. Joao C, Freitas J, Gomes F, et al. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. Ann Hematol. 2016;95(6):931–6. doi: 10.1007/s00277-016-2662-6.
  15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006.
  16. U.S. department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0; 2010. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed 21.05.2024).
  17. Ranganathan P, Gunasekaran V, Singhvi I, Ansari MJ. Development and validation of Lenalidomide in human plasma by LC-MS/MS. Saudi J Biol Sci. 2019;26(7):1843–7. doi: 10.1016/j.sjbs.2018.02.006.
  18. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi: 10.1016/S1470-2045(16)30206-6.
  19. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337–41. doi: 10.1080/10428190601126602.
  20. Gonsalves WI, Leung N, Rajkumar SV, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5(3):e296. doi: 10.1038/bcj.2015.20.
  21. Семочкин С.В., Желнова Е.И., Мисюрина Е.Н. и др. Клиническое значение восстановления функции почек у больных впервые диагностированной множественной миеломой, осложненной тяжелой и диализ-зависимой почечной недостаточностью. Гематология и трансфузиология. 2019;64(3):283–96. doi: 10.35754/0234-5730-2019-64-3-283-296. [Semochkin S.V., Zhelnova E.I., Misyurina E.N., et al. Clinical importance of renal recover on outcomes of newly diagnosed multiple myeloma patients with severe and dialysis-dependent kidney failure. Russian journal of hematology and transfusiology. 2019;64(3):283–96. doi: 10.35754/0234-5730-2019-64-3-283-296. (In Russ)]
  22. Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019. Leuk Lymphoma. 2021;62(6):1386–95. doi: 10.1080/10428194.2020.1867725.
  23. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109(6):2604–6. doi: 10.1182/blood-2006-09-046409.
  24. Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28(30):4635–41. doi: 10.1200/JCO.2010.28.1238.
  25. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91(5):499–502. doi: 10.1002/ajh.24335.
  26. Bridoux F, Chen N, Moreau S, et al. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. Cancer Chemother Pharmacol. 2016;78(1):173–82. doi: 10.1007/s00280-016-3068-9.
  27. Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012;69(3):789–97. doi: 10.1007/s00280-011-1760-3.
  28. Mikhael J, Manola J, Dueck AC, et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 2018;8(9):86. doi: 10.1038/s41408-018-0110-7.
  29. Cerchione C, Nappi D, Pareto AE, et al. Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience. Anticancer Drugs. 2018;29(4):371–2. doi: 10.1097/CAD.0000000000000604.
  30. Sidana S, Kumar S, Fraser R, et al. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2022;28(2):83.e1–83.e9. doi: 10.1016/j.jtct.2021.10.022.
  31. Jian Y, Zhou H, Xie W, et al. Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China. Am J Cancer Res. 2023;13(4):1571–81.
  32. Lazana I, Floro L, Christmas T, et al. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. Bone Marrow Transplant. 2022;57(6):959–65. doi: 10.1038/s41409-022-01657-y.
  33. St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50(1):95–9. doi: 10.1038/bmt.2014.226.
  34. Мисюрина Е.Н., Барях Е.А., Фролова Н.Ф. и др. Основные терапевтические подходы к ведению больных онкогематологического профиля с новой коронавирусной инфекцией (COVID-19). Онкогематология. 2023;18(4):10–39. doi: 10.17650/1818-8346-2023-18-4(Suppl)-10-39. [Misyurina E.N., Baryakh E.A., Frolova N.F., et al. Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19). Oncohematology. 2023;18(4):10–39. doi: 10.17650/1818-8346-2023-18-4(Suppl)-10-39. (In Russ)]
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Clinical Oncohematology